PASG News and Press, Passage Bio Inc. From 03/06/23

Presented additional interim data at 19 th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023 Planned ex...

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 1 for the initial award in the fall of 2023 PHILADELPHIA, March 01, 2023 (GLOBE NEWSWIRE) -- Passage Bi...

Summary Passage Bio’s most advanced gene therapy reported good early Phase 1 data. Over $200 million in cash should provide funding until more data is available. The price is way under the IPO price, despite the potential of the platform. For further det...

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, will partic...

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m....

Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of PBGM01 led to a biological effect in patients PBGM01 administration resulted in stabilization of MRI severity scores in all treated patients through 6 to twelve m...

– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations PHILADELPHIA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines com...

PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passa...

Passage Bio ( NASDAQ: PASG ) announced Wednesday new interim results from the first six patients in its Phase 1/2 study for gene therapy PBGM01 targeted at GM1 Gangliosidosis (GM1), a rare, genetically driven form of lysosomal storage disease. Passage Bio ( PASG ) shares rose ~17% in ...

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profile Intra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosides ...